Tuesday, May 14, 2013

Nexium MDL Established

As a result of the ongoing lawsuits over Nexium bone fracture side effects and the fact that the number of the lawsuits keeps increasing, 39 of the filed cases were consolidated by the U.S. Judicial Panel as of December 2012. 

The lawsuits in the Nexium MDL claim that Nexium, created by manufacturer, AstraZeneca LP, causes side effects such as bone loss, which subsequently has resulted in fractures and similar symptoms. To counter the multidistrict litigation, AstraZeneca argued that there are still lingering questions -- namely product identification and distinct causation questions -- that justify their argument to keep the lawsuits separate.

California's Central District will be the court. 

Court data updated on March 5th, 2013, by the US Judicial Panel on Multi-District Litigation (MDL), indicate that there are 42 actions currently pending in the Nexium MDL (U.S. District Court, Central District of California, MDL 2404). Nexium, manufactured by AstraZeneca, is a proton pump inhibitor (PPI) prescribed for the treatment of heartburn, acid-reflux, and inflammation of the esophagus. Plaintiffs allege that Nexium may cause a variety of bone ailments —in particular, osteoporosis, loss of bone density, and bone fractures— and that AstraZeneca failed to adequately warn of these potential adverse side effects.